Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Research roundup: Young women and delays in breast cancer diagnosis

Adolescents and young adults (ages 15-39) make up 5 and 6 percent of all breast cancer cases in the United States and have the lowest five-year survival rates.

30 Apr 2013

Biventricular pacing best in atrioventricular block patients

Use of biventricular rather than conventional right ventricular pacing results in better clinical outcomes in patients who have heart failure with atrioventricular block and left ventricular systolic dysfunction, show the results of BLOCK HF.

29 Apr 2013

CVRx enrolls first patient in Barostim HOPE4HF clinical trial

CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients.

29 Apr 2013

Heart Failure Congress 2013 to feature more than 100 scientific sessions on heart failure

The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.

29 Apr 2013

JHUSON opens registration for first-ever MOOC

Prospective students, lifelong learners, or anyone simply interested in patient safety can get a thorough overview of the topic and a taste of the Johns Hopkins educational experience beginning June 3.

29 Apr 2013

Renal denervation reduces blood pressure for patients not responding to drug therapy

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.

26 Apr 2013

Mayo Clinic implements electronic warning system to identify patients at risk of QT-related deaths

Using a one-of-a-kind computer-aided program, Mayo Clinic has developed and implemented a Mayo-wide electronic warning system to identify patients at risk of QT-related deaths from an abnormality in the heart's electrical system.

26 Apr 2013

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome.

25 Apr 2013

Transplant, MCS physicians examine value of hTEE management at symposium in Montreal

ImaCor Inc., the developer of the world's only hemodynamic transesophageal echocardiography management device, announced today that transplant and mechanical circulatory support physicians from around the world gathered in Montreal at an hTEE symposium to hear from heart failure experts about the value of hTEE management.

25 Apr 2013

Omega-3 polyunsaturated fatty acids associated with lower risk of heart failure mortality in adults

Omega-3 polyunsaturated fatty acids, namely DHA and EPA found in fatty fish, are associated with lower risk of heart failure mortality in adults with chronic heart failure or who have experienced a heart attack.

25 Apr 2013

American Heart Association: Direct, indirect costs to treat heart failure could more than double in 2030

By 2030, you - and every U.S. taxpayer - could be paying $244 a year to care for heart failure patients, according to an American Heart Association policy statement.

25 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

Highly active ART does not appear to impair heart function, study suggests

Long-term use of highly active antiretroviral therapies does not appear to be associated with impaired heart function in children and adolescents in a study that sought to determine the cardiac effects of prolonged exposure to HAART on children infected with the human immunodeficiency virus, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA.

18 Apr 2013

Reducing preventable hospital readmissions may take longer, say researchers

Achieving widespread reductions in preventable hospital readmissions among Medicare beneficiaries may take longer than many health care professionals originally anticipated, according to researchers at Penn State, the Weill Cornell Medical College and the University of Pennsylvania.

18 Apr 2013

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.

18 Apr 2013

Loyola University Medical Center physicians deploy aortic valve through patient's abdomen

In a first-of-its-kind procedure in the United States, Loyola University Medical Center physicians have deployed an aortic valve by going through a patient's abdomen.

18 Apr 2013

EKG could predict cardiovascular illness

A common test that records the heart's electrical activity could predict potentially serious cardiovascular illness, according to a UC San Francisco-led study.

17 Apr 2013

Heart Failure News and Research

Further Reading

Research roundup: Young women and delays in breast cancer diagnosis

Biventricular pacing best in atrioventricular block patients

CVRx enrolls first patient in Barostim HOPE4HF clinical trial

Heart Failure Congress 2013 to feature more than 100 scientific sessions on heart failure

JHUSON opens registration for first-ever MOOC

Renal denervation reduces blood pressure for patients not responding to drug therapy

Mayo Clinic implements electronic warning system to identify patients at risk of QT-related deaths

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Transplant, MCS physicians examine value of hTEE management at symposium in Montreal

Omega-3 polyunsaturated fatty acids associated with lower risk of heart failure mortality in adults

American Heart Association: Direct, indirect costs to treat heart failure could more than double in 2030

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Unavoidable damage to heart and lungs can be limited by using CVD drug

Highly active ART does not appear to impair heart function, study suggests

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Study: Shock wave-facilitated cell therapy improves outcomes in patients with chronic heart failure

Reducing preventable hospital readmissions may take longer, say researchers

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

Loyola University Medical Center physicians deploy aortic valve through patient's abdomen

EKG could predict cardiovascular illness

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News